- Home
- SEED vs ADXN Comparison
SEED vs ADXN Comparison
Compare SEED & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEED | ADXN |
|---|---|---|
| Founded | 1997 | 2002 |
| Country | China | Switzerland |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 10.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SEED | ADXN |
|---|---|---|
| Price | $1.13 | $7.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 28.5K | 9.0K |
| Earning Date | 01-30-2026 | 12-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,823,070.00 | $198,824.00 |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.74 | $6.51 |
| 52 Week High | $2.70 | $12.05 |
Technical Indicators
Market Signals| Indicator | SEED | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 36.61 | 45.80 |
| Support Level | $1.17 | $7.60 |
| Resistance Level | $1.36 | $8.00 |
| Average True Range (ATR) | 0.08 | 0.38 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 3.85 | 44.56 |
Price Performance
Historical ComparisonAbout SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.